Regeneron's Eylea Soars, But Praluent Is Slow Out Of The Gate
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech points to slow reimbursement pace in the US for PCSK9 inhibitors, but the bigger issue may be awaiting CV outcomes data. Eylea continued its exponential sales growth, however, as Regeneron seeks to add to its label.